156 related articles for article (PubMed ID: 35481695)
1. PD-1/PD-L1 co-location: A novel biomarker for immunotherapy response in non-small cell lung cancer.
Diao X; Guo C; Li S
Thorac Cancer; 2022 Jun; 13(11):1545-1547. PubMed ID: 35481695
[No Abstract] [Full Text] [Related]
2. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
[TBL] [Abstract][Full Text] [Related]
4. [Current challenges with PD-L1 testing for immunotherapy biomarkers in non-small cell lung cancer].
Li Y; Chen J
Zhonghua Bing Li Xue Za Zhi; 2019 Aug; 48(8):585-589. PubMed ID: 31422587
[TBL] [Abstract][Full Text] [Related]
5. Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context.
Wiesweg M; Mairinger F; Reis H; Goetz M; Kollmeier J; Misch D; Stephan-Falkenau S; Mairinger T; Walter RFH; Hager T; Metzenmacher M; Eberhardt WEE; Zaun G; Köster J; Stuschke M; Aigner C; Darwiche K; Schmid KW; Rahmann S; Schuler M
Eur J Cancer; 2020 Nov; 140():76-85. PubMed ID: 33059196
[TBL] [Abstract][Full Text] [Related]
6. Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non-Small Cell Lung Cancer to Receive Immunotherapy.
Mansfield AS; Dong H
Clin Pharmacol Ther; 2016 Sep; 100(3):220-2. PubMed ID: 26916808
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
Wang Z; Duan J; Cai S; Han M; Dong H; Zhao J; Zhu B; Wang S; Zhuo M; Sun J; Wang Q; Bai H; Han J; Tian Y; Lu J; Xu T; Zhao X; Wang G; Cao X; Li F; Wang D; Chen Y; Bai Y; Zhao J; Zhao Z; Zhang Y; Xiong L; He J; Gao S; Wang J
JAMA Oncol; 2019 May; 5(5):696-702. PubMed ID: 30816954
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data.
Aguiar PN; De Mello RA; Hall P; Tadokoro H; Lima Lopes G
Immunotherapy; 2017 May; 9(6):499-506. PubMed ID: 28472902
[TBL] [Abstract][Full Text] [Related]
9. PD-L1
Zhang L; Zhang X; Liu Y; Zhang T; Wang Z; Gu M; Li Y; Wang DD; Li W; Lin PP
Cancer Lett; 2020 Jan; 469():355-366. PubMed ID: 31678168
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in Advanced Non-Small Cell Lung Cancer.
Huang J; Reckamp KL
Semin Respir Crit Care Med; 2020 Jun; 41(3):400-408. PubMed ID: 32450594
[TBL] [Abstract][Full Text] [Related]
11. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
12. Real-world evidenceand clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors.
Song P; Zhang J; Shang C; Zhang L
Sci Rep; 2019 Mar; 9(1):4278. PubMed ID: 30862891
[TBL] [Abstract][Full Text] [Related]
13. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
Front Immunol; 2021; 12():646874. PubMed ID: 33927719
[TBL] [Abstract][Full Text] [Related]
14. Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer.
Lafuente-Sanchis A; Zúñiga Á; Estors M; Martínez-Hernández NJ; Cremades A; Cuenca M; Galbis JM
Clin Lung Cancer; 2017 Mar; 18(2):e109-e116. PubMed ID: 27816393
[TBL] [Abstract][Full Text] [Related]
15. Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non-Small Cell Lung Cancer.
Li JX; Huang JM; Jiang ZB; Li RZ; Sun A; Lai-Han Leung E; Yan PY
Integr Cancer Ther; 2019; 18():1534735419890020. PubMed ID: 31838881
[TBL] [Abstract][Full Text] [Related]
16. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
17. DNA damage response signaling as a predictive biomarker and synergistic therapeutic target for anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
Zhu Z; Chen P; Yan Z
Thorac Cancer; 2018 Aug; 9(8):901-903. PubMed ID: 29932513
[No Abstract] [Full Text] [Related]
18. Effect and biomarker of Nivolumab for non-small-cell lung cancer.
Wang L; Zhao D; Qin K; Rehman FU; Zhang X
Biomed Pharmacother; 2019 Sep; 117():109199. PubMed ID: 31387181
[TBL] [Abstract][Full Text] [Related]
19. The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy.
Villaruz LC; Socinski MA
Clin Pharmacol Ther; 2016 Sep; 100(3):212-4. PubMed ID: 27090296
[TBL] [Abstract][Full Text] [Related]
20. [Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer].
Lupo A; Alifano M; Wislez M; Boulle G; Velut Y; Biton J; Cremer I; Goldwasser F; Leroy K; Damotte D
Rev Pneumol Clin; 2018 Oct; 74(5):339-350. PubMed ID: 30337201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
